Synthesis and evaluation of 5-substituted derivatives of 4,5-dihydro-3,3-diethyl-2(3H)-furanone as subtype-selective muscarinic leads

Medicinal Chemistry Research

Volumn 12, Issue 9, 2003, Pages 481-511

  Ahungena, Alemayyehu ^a   Gabriel, Jerome L ^b   Canney, Daniel J ^a  

^a TEMPLE UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3 DIETHYL 4,5 DIHYDRO 5 [(2 ISOPROPYLIMIDAZOL 1 YL)ETHYL] 2(3H) FURANONE; 3,3 DIETHYL 4,5 DIHYDRO 5 [(2 ISOPROPYLIMIDAZOL 1 YL)METHYL] 2(3H) FURANONE; 3,3 DIETHYL 4,5 DIHYDRO 5 [(2 METHYLIMIDAZOL 1 YL)METHYL] 2(3H) FURANONE; 3,3 DIETHYL 4,5 DIHYDRO 5 [(2 PROPYLIMIDAZOL 1 YL)METHYL] 2(3H) FURANONE; 3,3 DIETHYL 4,5 DIHYDRO 5 [(IMIDAZOL 1 YL)ETHYL] 2(3H) FURANONE; 3,3 DIETHYL 4,5 DIHYDRO 5 HYDROXYETHYL 2(3H) FURANONE; 3,3 DIETHYL 4,5 DIHYDRO 5 IODOETHYL 2(3H) FURANONE; 3,3 DIETHYL 4,5 DIHYDRO 5 MORPHOLINOETHYL 2(3H) FURANONE; 3,3 DIETHYL 4,5 DIHYDRO 5 PIPERIDINOETHYL 2(3H) FURANONE; 3,3 DIETHYL 5 IMIDAZOLYLMETHYL 2(3H) FURANONE; 5 [(2 ETHYLIMIDAZOL 1 YL)METHYL] 3,3 DIETHYL 4,5 DIHYDRO 2(3H) FURANONE; ALKYL GROUP; CHOLINERGIC RECEPTOR; FURANONE DERIVATIVE; IMIDAZOLE DERIVATIVE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SPECIFICITY; DRUG SYNTHESIS; MOUSE; NONHUMAN; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 3242878467     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. a) Levine, R. R. et al. Proceedings of the eighth international symposium on subtypes of muscarinic receptors. Life Sci. 1999, 64, 355-593.
2. b) Levine, R. R. et al. Proceedings of the ninth international symposium on subtypes of muscarinic receptors. Life Sci. 2001, 65, 355-593.
3. c) Caulfield, M. P., Birdsall, N. J. M. International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 1998, 50, 279-290.
4. Sargent, P. The Diversity of neuronal nicotinic receptors. Annu. Rev. Neurosci. 1993, 16, 403-443.
5. a) Wess, J. Novel insights into muscarinic acetylcholine receptor function using gene targeting technology. T.I.P.S. 2003, 24, 414-420.
6. b) Felder, C. C. et al. Therapeutic opportunities for muscarinic receptors in the central nervous system. J. Med. Chem. 2000, 43, 4333-4353.
7. c) Eglen, R.M., et al. Muscarinic receptor ligands and their therapeutic potential. Curr. Opin. Chem. Biol. 1999, 3, 426-432.
8. a) Schmitt, J.D.; Bencherif, M. Targeting nicotinic acetylcholine receptors: Advances in molecular design and therapies. In Annual Reports in Med. Chem., Vol 35, Robertson, Ed., Academic press, Inc, 2000, pp 41-51 (and references cited therein).
9. b) Lloyd, G. K.; Williams, M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J.P.E.T. 2000, 292, 461-467.
10. c) Nielsen, S. F.; Nielsen, E. O.; Olsen, G. M.; Liljefors, T.; Peters, D. Novel potent ligands for the central nicotinic acetylcholine receptor: Synthesis, receptor binding, and 3D-QSAR analysis. J. Med. Chem. 2000, 43, 2217-2226.
11. d) Maelicke, A.; Albuquerque, E. X. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's Disease. Europ. J. Pharmacol. 2000, 393, 165-170.
12. e) Meyer, M. D.; Decker, M. W.; Rueter, L. E.; Anderson, D. J.; Dart, M. J.; Kim, K. H.; Sullivan, J. P.; Williams, M. The identification of novel structural compound classes exhibiting high affinity for neuronal nicotine acetylcholine receptors and analgesic efficacy in preclinical models of pain. Europ. J. Pharmacol. 2000, 393, 171-177.
13. f) Holladay, M.W.; Dart, M.J.; Lynch, J.K. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. 1997, 40, 4169-4194.
14. a) Kaiser, C.; Spagnuolo, C. J.; Adams, T. C.; Audia, V. H.; Dupont, A.C.; Hatoum, H.; Lowe, V. C.; Prosser, J. C.; Sturm, B. L.; Noronha-Blob, L. Synthesis and antimuscarinic properties of some N-substituted 5-(aminomethyl)-3,3-diphenyl-(3H)-furanones. J. Med. Chem. 1992, 55, 4415-4424.
15. b) Flavin, M.T.; Lu, M.C.; Thompson, E.B.; Bhargava, H.N. Molecular modification of anticholinergics as probes for muscarinic receptors. 3. Conformationally restricted analogues of benactyzine. J. Med. Chem. 1987, 30, 278-285.
16. Beers, W. H.; Reich, E. Structure and activity of acetylcholine. Nature 1970, 228, 917-922.
17. Sheridan, R.P.; Nilakantan, R.; Dixon, J.S.; Venkataraghavan, R. The Ensemble approach to distance geometry: Application to the nicotinic pharmacophore. J. Med. Chem. 1986, 29, 899-906.
18. a) Glennon, R. A.; Herndon J. L.; Dukat, M. Epibatidine-Aided studies toward definition of a nicotine receptor pharmacophore. Med. Chem. Res., 1994, 4, 461-473.
19. b) Dukat, M.; Damaj, M. I.; Glassco, W.; Dumas, D.; May, E. L.; Martin, B. R.; Glennon, R. A. Epibatidine: A very high affinity nicotine-receptor ligand. Med. Chem Res., 1993, 4, 131-39.
20. c) Cheng, Y.-X.; Dukat, M.; Dowd, M.; Fiedler, W.; Martin, B.; Damaj, M. I.; Glennon, R.A. Synthesis and binding of 6,7,8,9-tetrahydro-5H-pyrido[3,4-d] azepine and related ring-opened analogs at central nicotinic receptors. Eur. J. Med. Chem. 1999, 34, 177.
21. d) Glennon, R.A.; Dukat, M. Central nicotinic receptor ligands and pharmacophores. Pharm. Acta Helv. 2000, 74, 103-114.
22. Schmitt, J.D.; Sharpless, C. G. V.; Caldwell, W.S. Molecular recognition in nicotinic receptor: The importance of π-cation interaction. J. Med. Chem. 1999, 42, 3066-3074.
23. a) Tonder, J.E.; Hansen J. B.; Begtrup, M.; Pettersson, I.; Rimvall, K.; Christensen, B.; Ehrbar, U.; Olesen, P. H. Improving the nicotinic pharmacophore with a series of (isoxazole)methylene-1-azacyclic compounds: Synthesis, structure-activity relationship, and molecular modeling. J. Med. Chem. 1999, 42, 4970-4980.
24. 3H]-N-methylcarbamylcholine. J. Comp-Aided Mol. Des. 2001, 15, 247-258.
25. Curtis, L.; Chiodini, F.; Spang, J.E.; Bertrand, S.; Patt, J.T.; Westera, G.; Bertrand, D. A new look at the neuronal nicotinic acetylcholine receptor pharmacophore. Eur. J. Pharmacol. 2000, 393, 155-163.
26. a) Shapiro, G.; Floersheim, P.; Boelsterilli, J.; Amstutz, R.; Bolliger, G.; Gammenthaler, H.; Gmelin, G.; Supavilai, P.; Walkinshaw, M. Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the ml receptor. J. Med. Chem. 1992, 35, 15-27.
27. b) Nordvall, G.; Hacksell, U. Binding-Site modeling of the muscarinic ml receptor: A combination or homology-based and indirect approaches. J. Med. Chem. 1993, 36, 967-976.
28. 3 receptor antagonists. J. Med. Chem. 1999, 42, 3210-3216.
29. a) Ahungena, A.; Canney, D.J. Synthesis and biological evaluation of aminomethyl/amidomethyl derivatives of an anticonvulsant gamma-butyrolactone. Med. Chem. Res. 1996, 6:9, 618-634.
30. b) Bartlett, P. A.; Richardson, D. P.; Myerson, J. Electrophilic lactonization as a tool in acyclic stereocontrol. Synthesis of Serricomin. Tetrahedron 1984, 40, 2317-2327.
31. c) Chamberlin, A.R.; Dezube, M.; Dussault, P.; McMills, M.C. Iodolactonization of allylic alcohol derivatives containing internal nucleophiles. Control of stereoselectivity by substituents in acyclic precursors. J. Am. Chem. Soc. 1983, 105, 5819-5825.
32. Smissman, E.E.; Schnettler, R.A.; Portoghese, P.S. Mechanism of the Prins Reaction. Stereoaspects of the formation of 1,3-Dioxanes. J. Org. Chem. 1965, 30, 797-801.
33. McOmie, J. F. W.; Watts, M. L.; West, D. E. Demethylation of aryl methyl ethers by boron tribromide. Tetrahedron 1968, 24, 2289-2292.
34. Zoller, T.; Uguen, D.; DeClan, A.; Fischer, J. Efficient preparation of E-β-iodovinyl phenylsulfone by Finkelstein reaction at a vinyl center. Tetrahedron Letters 1998, 39, 8089-8092.
35. Gabriel, J.L.; Mitchell, W.M. Proposed atomic structure of a truncated human immunodeficiency virus glycoprotein gp120 derived by molecular modeling: Target CD4 recognition and docking mechanism. Proc. Natl. Acad. Sci. USA 1993, 90, 4186-4191.
36. Gabriel, J. L.; Mitchell, W. M. HIV GP120 docking interactions and inhibitor design based on an atomic structure derived by molecular modeling using the DREIDING II force field. In protein folds: A distance-based approach, Bohr, H.; Brunak, S., Eds.; 1996, 294-307.
37. Canney, D., J., et.al., Synthesis and preliminary biological evaluation of 3-substited quinuclidines as nicotinic ligands. Med Chem Res. 1997, 7:5, 282-300.
38. 2 muscarinic receptor subtypes. Life Sciences 1983, 32, 3001-3011.
39. 3H]Pirenzepine and [3H]QNB binding to brain muscarinic cholinergic receptors. Mol. Pharmacol. 1984, 26, 161-169.
40. Hammer, R., Giraldo, E. et al. Binding profile of a novel cardioselective muscarine receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat. Life Sciences 1986, 38, 1653-1662.
41. 2 receptor antagonist. Life Sciences 1986, 38, 1663-1672.
42. 3 receptors. Digestion 1990, 45, 196-201.
43. 3 Muscarinic cholinergic receptors: binding characteristics of agonists and antagonists. J. Neurolog. Sci. 1990, 97, 67-80.
44. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
45. Pabreza, L. A.; Dhawan, S.; Kellar. K. J. [3H] Cytisine binding to nicotinic cholinergic receptors in brain. Molec Pharmacol. 1990, 39, 9-12.
46. Scott, R. W.; Goode, T. L.; Raffa, R.B. Pilocarpine-induced reciprocal hindlimb scratching in mice. Pharmacol. Biochem. Behav. 1987, 26, 327-331.
47. 1 type receptors. Life Sciences 1987, 41, 1831-1836.
48. Raffa, R.B.; Ortegon, M.E.; Watson, M. Reciprocal hindlimb scratching and putative subtype-selective muscarinic agents. Eur. J. Pharmacol. 1988, 158, 289-292.